<div id="readability-page-1">Novo Nordisk A/S ( NVO ) shares are trading lower on Thursday after the company was hit with a lawsuit from compounding pharmacy Strive Specialties. <ul> <li>Novo Nordisk ( NVO ) stock is feeling bearish pressure. What’s behind NVO decline?</li> </ul> <h2>The Legal Battle Over Weight-Loss Drug Monopoly</h2> Strive Specialties filed a lawsuit on Wednesday in a federal district court in San Antonio, Texas, alleging that Novo Nordisk ( NVO ) and Eli Lilly ( LLY ) and Co illegally blocked access to customized versions of their blockbuster weight-loss medicines, reported Reuters. Strive filed the suit, alleging Novo Nordisk ( NVO ) and Eli Lilly ( LLY ) illegally blocked access to customized, lower‑cost versions of their popular GLP‑1 weight‑loss drugs. The pharmacy believes the two companies used their dominance in the market to keep patients from getting compounded alternatives to medications like Ozempic and Wegovy, and alleged they struck exclusive deals with major telehealth platforms that stopped doctors from prescribing compounded GLP‑1s even when a tailored dose was needed. Strive also said the companies interfered with its relationships with payment processors and tech partners, arguing that compounders stepped in during shortages and still provide options brand‑name drugs don't. The pharmacy is seeking monetary damages and a court order preventing Novo and Lilly from enforcing the alleged exclusivity agreements. Novo responded by saying, “the claims in this litigation are without merit, and we will vigorously defend against them in court.” NVO Price Action: Novo Nordisk ( NVO ) shares were down 3.40% at $56.91 at the time of publication on Thursday, according to Benzinga Pro. Image: Shutterstock</div>

诺和诺德公司

诺和诺德公司 (NYSE:NVO) 的股价下跌了 3.40%，至 56.91 美元，此前该公司面临来自 Strive Specialties 的诉讼。诉讼指控诺和诺德和礼来公司非法阻止患者获得定制的、低成本的 GLP-1 减肥药版本，声称他们利用市场主导地位阻止患者获取复合替代品。Strive 请求经济赔偿和针对独占协议的法院命令。诺和诺德表示，这些指控毫无根据，他们将在法庭上积极辩护

由于诺和诺德公司面临 GLP-1 反垄断诉讼，其股票出现下跌